RVAC Medicines Pte. Ltd., a Singapore-based messenger RNA (mRNA) technology platform company incubated by CBC Group, announced on Wednesday that it has dosed a participant in a phase one, first-in-human study assessing the company's mRNA-based COVID-19 vaccine candidate, RVM-V001.
The Phase 1 study, an open-label, dose escalation study, is intended to assess the safety and immunogenicity of RVM-V001 in around 54 healthy adults in Australia.
This study is part of a series of clinical trials intended to assess RVAC's range of COVID-19 vaccine candidates that include one against the ancestral strain, one against the Omicron strain and a bivalent vaccine candidate with components of both ancestral and Omicron strains.
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Lipocine doses first cohort in LPCN 1154 study
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates